Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SURFACE ONCOLOGY, INC.

(SURF)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
7.9(c) 7.69(c) 7.75(c) 7.62(c) 7.52(c) Last
2 531 884 1 845 164 1 498 200 1 201 985 795 873 Volume
-3.30% -2.66% +0.78% -1.68% -1.31% Change
More quotes
Financials (USD)
Sales 2021 29,8 M - -
Net income 2021 -49,6 M - -
Net Debt 2021 - - -
P/E ratio 2021 -6,52x
Yield 2021 -
Sales 2022 11,0 M - -
Net income 2022 -73,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -4,81x
Yield 2022 -
Capitalization 327 M 327 M -
Capi. / Sales 2021 11,0x
Capi. / Sales 2022 29,7x
Nbr of Employees 51
Free-Float 90,2%
More Financials
Company
Surface Oncology, Inc. is a clinical-stage immuno-oncology company. The Company is engaged in the development of cancer immunotherapies. To unlock the potential of cancer immunotherapy, the Company is targeting a set of immune processes by which cancer cells evade immune recognition and attack. Its programs are built upon insights about how to improve the immune system’s recognition and elimination of cancer cells. 
More about the company
Ratings of Surface Oncology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about SURFACE ONCOLOGY, INC.
06/10SURFACE ONCOLOGY, INC.  : Submission of Matters to a Vote of Security Holders (f..
AQ
06/04SECTOR UPDATE : Health Care Stocks Trade Higher Pre-Bell Friday
MT
06/04Surface Oncology in Clinical Trial Collaboration With Roche
DJ
06/04SURFACE ONCOLOGY  : to Collaborate With Roche for Testing Liver Cancer Combinati..
MT
06/04SURFACE ONCOLOGY  : SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monoth..
PU
06/04SURFACE ONCOLOGY, INC.  : Other Events, Financial Statements and Exhibits (form ..
AQ
06/04SRF388, a First-in-Class IL-27 Antibody, Demonstrates Monotherapy Activity in..
GL
06/04SURFACE ONCOLOGY  : to Collaborate with Roche on Immuno-Oncology Study Evaluatin..
AQ
06/04Surface Oncology to Collaborate with Roche on Immuno-Oncology Study Evaluatin..
GL
05/18SURFACE ONCOLOGY  : BTIG Initiates Surface Oncology at Buy Rating With $17 Price..
MT
05/05SURFACE ONCOLOGY  : Earnings Flash (SURF) SURFACE ONCOLOGY Posts Q1 Revenue $1.6..
MT
05/05SURFACE ONCOLOGY  : Management's Discussion and Analysis of Financial Condition ..
AQ
05/05SURFACE ONCOLOGY  : Reports Financial Results and Corporate Highlights for First..
PU
05/05SURFACE ONCOLOGY, INC.  : Results of Operations and Financial Condition, Financi..
AQ
05/03SURFACE ONCOLOGY, INC.  : Entry into a Material Definitive Agreement (form 8-K)
AQ
More news
News in other languages on SURFACE ONCOLOGY, INC.
06/04ROCHE  : un partenariat clinique dans le cancer du foie
03/09MERCK  : un accord de collaboration avec Surface Oncology
More news
Analyst Recommendations on SURFACE ONCOLOGY, INC.
More recommendations
Chart SURFACE ONCOLOGY, INC.
Duration : Period :
Surface Oncology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SURFACE ONCOLOGY, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 16,00 $
Last Close Price 7,52 $
Spread / Highest target 139%
Spread / Average Target 113%
Spread / Lowest Target 86,2%
EPS Revisions
Managers and Directors
NameTitle
Robert W. Ross President, Chief Executive Officer & Director
Jessica Fees Chief Financial Officer
J. Jeffrey Goater Chairman
Vito J. Palombella Chief Scientific Officer
Alison M. O'Neill Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
SURFACE ONCOLOGY, INC.-18.61%327
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966